Question

In the EMPA-REG Outcomes Trial, patients on empa experience a lower incidence of Death from any Cause, which resulted in a relative risk reduction of What?

Answer 1

The EMPA-REG Outcomes Trial found that empagliflozin reduced the relative risk of death from any cause in patients with type 2 diabetes; the specific percentage of risk reduction is not provided.

Step-by-step explanation:

The EMPA-REG Outcomes Trial investigated the effects of the medication empagliflozin on patients with type 2 diabetes at high risk for cardiovascular events. This trial found that patients on empagliflozin experienced a lower incidence of death from any cause, resulting in a significant relative risk reduction. Relative risk is a measure of the strength of an association between exposure to a treatment and an outcome. In the context of the EMPA-REG trial, a relative risk less than one indicates that the treatment is associated with a lower risk of the outcome, which in this case is death. Unfortunately, the exact percentage of the relative risk reduction is not provided in the details given, therefore the specific numerical value cannot be cited.